

RESEARCH

Open Access

# The pleiotropic effects of prebiotic galacto-oligosaccharides on the aging gut



Jason W. Arnold<sup>1,2</sup>, Jeffery Roach<sup>2,3</sup>, Salvador Fabela<sup>1,2,4</sup>, Emily Moorfield<sup>5</sup>, Shengli Ding<sup>5</sup>, Eric Blue<sup>5</sup>, Suzanne Dagher<sup>6</sup>, Scott Magness<sup>7</sup>, Rita Tamayo<sup>8</sup>, Jose M. Bruno-Barcena<sup>6</sup> and M. Andrea Azcarate-Peril<sup>1,2\*</sup>

## Abstract

**Background:** Prebiotic galacto-oligosaccharides (GOS) have an extensively demonstrated beneficial impact on intestinal health. In this study, we determined the impact of GOS diets on hallmarks of gut aging: microbiome dysbiosis, inflammation, and intestinal barrier defects (“leaky gut”). We also evaluated if short-term GOS feeding influenced how the aging gut responded to antibiotic challenges in a mouse model of *Clostridioides difficile* infection. Finally, we assessed if colonic organoids could reproduce the GOS responder—non-responder phenotypes observed in vivo.

**Results:** Old animals had a distinct microbiome characterized by increased ratios of non-saccharolytic versus saccharolytic bacteria and, correspondingly, a lower abundance of  $\beta$ -galactosidases compared to young animals. GOS reduced the overall diversity, increased the abundance of specific saccharolytic bacteria (species of *Bacteroides* and *Lactobacillus*), increased the abundance of  $\beta$ -galactosidases in young and old animals, and increased the non-saccharolytic organisms; however, a robust, homogeneous bifidogenic effect was not observed. GOS reduced age-associated increased intestinal permeability and increased *MUC2* expression and mucus thickness in old mice. Clydamycin reduced the abundance *Bifidobacterium* while increasing *Akkermansia*, *Clostridium*, *Coprococcus*, *Bacillus*, *Bacteroides*, and *Ruminococcus* in old mice. The antibiotics were more impactful than GOS on modulating serum markers of inflammation. Higher serum levels of IL-17 and IL-6 were observed in control and GOS diets in the antibiotic groups, and within those groups, levels of IL-6 were higher in the GOS groups, regardless of age, and higher in the old compared to young animals in the control diet groups. RTqPCR revealed significantly increased gene expression of TNF $\alpha$  in distal colon tissue of old mice, which was decreased by the GOS diet. Colon transcriptomics analysis of mice fed GOS showed increased expression of genes involved in small-molecule metabolic processes and specifically the respirasome in old animals, which could indicate an increased oxidative metabolism and energetic efficiency. In young mice, GOS induced the expression of binding-related genes. The galectin gene *Lgals1*, a  $\beta$ -galactosyl-binding lectin that bridges molecules by their sugar moieties and is an important modulator of the immune response, and the PI3K-Akt and ECM-receptor interaction pathways were also induced in young mice. Stools from mice exhibiting variable bifidogenic response to GOS injected into colon organoids in the presence of prebiotics reproduced the response and non-response phenotypes observed in vivo suggesting that the composition and functionality of the microbiota are the main contributors to the phenotype.

(Continued on next page)

\* Correspondence: [azcarate@med.unc.edu](mailto:azcarate@med.unc.edu)

<sup>1</sup>Department of Medicine, Division of Gastroenterology and Hepatology, School of Medicine, University of North Carolina, Chapel Hill, NC, USA

<sup>2</sup>UNC Microbiome Core, Center for Gastrointestinal Biology and Disease (CGIBD), School of Medicine, University of North Carolina, Chapel Hill, NC, USA

Full list of author information is available at the end of the article



© The Author(s). 2021, corrected publication February 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

(Continued from previous page)

**Conclusions:** Dietary GOS modulated homeostasis of the aging gut by promoting changes in microbiome composition and host gene expression, which was translated into decreased intestinal permeability and increased mucus production. Age was a determining factor on how prebiotics impacted the microbiome and expression of intestinal epithelial cells, especially apparent from the induction of galectin-1 in young but not old mice.

**Keywords:** Gut microbiome, Prebiotics, *Bifidobacterium*, Intestinal permeability, Host-microbiota interactions, Diet, Antibiotics, Metagenomics, Transcriptomics, Organoids

## Background

The fragility of the gut microbiota and consequent susceptibility to disease are accentuated at the beginning and at the end of life. The aging gut microbiome has a demonstrated altered bacterial diversity with reductions in the abundance of beneficial microorganisms [1–12]. Imbalances in the gut microbiota promote a basal inflammatory state and enhance susceptibility to viral and bacterial infections, including *Clostridioides difficile* [13–15]. The elderly human gut microbiome has been reported to have a reduced abundance of *Bifidobacterium*, *Faecalibacterium prausnitzii*, and *Clostridium* XIVa [2–4] and increased *Clostridium perfringens*, coliforms, enterococci [1], *Streptococcus*, *Staphylococcus*, and *Enterobacteria* [2, 3, 5–7]. Accordingly, the aging human gut microbiota shows a loss of genes involved in the production of short-chain fatty acids (SCFAs) and a decrease in saccharolytic potential, with a reduced representation of starch, sucrose, galactose, glycolysis, and gluconeogenesis metabolism pathways; a concomitant loss of fibrolytic microorganisms; and an overall increase in proteolytic function [16]. Consistent with human microbiome observations, old mice have a distinctive gut microbiome characterized by lower phylogenetic diversity, increased representation of potentially pathogenic taxa including *Rikenella* and *Enterobacteriaceae*, and reduced representation of di-, oligo-, and polysaccharide utilization genes [17].

The ability of bacteria to access host tissues is limited by the mucus layer in healthy individuals. In mice, the colon of old animals has a thinner firm mucus layer (< 10  $\mu\text{m}$ ) compared to young mice (20–25  $\mu\text{m}$ ), resulting in a failure to spatially compartmentalize the microbiota to the intestinal lumen [18, 19]. However, the number of mucus-producing goblet cells does not decline in the specialized follicle-associated epithelium in aged mice [20]. The mucus protein composition is relatively homogeneous along the intestine; however, the main mucin component synthesized and secreted by intestinal goblet cells, MUC2, shows region-specific O-glycan patterns [21, 22]. Changes in properties of the mucus barrier have been associated with shifts in bacterial community composition [23]. Conversely, beneficial microorganisms like *Lactobacillus plantarum* [24] and *Akkermansia muciniphila* [25] have been shown to promote an increase in

mucus thickness and improve host tight junctions in aging animals, reducing permeability. Likewise, *Bifidobacterium longum* and *B. longum* subsp. *infantis* provided protection against deterioration of the colonic mucus layer, counteracting negative influences of Western diets on mucus hyper-degradation by enhancing production [26, 27].

An increased inflammatory state is another hallmark of gut aging [28]. Aging changes the balance between inflammatory and anti-inflammatory cytokines favoring an excessive production of IL-6, TNF $\alpha$ , and IL-1 $\beta$ , directly affecting intestinal permeability [28, 29]. Traditionally, immuno-senescence, which is a decrease in the efficiency of the immune system over time, has been considered the largest contributor to increases in inflammatory mediators [30, 31]. However, recent studies have highlighted a prominent role of dysbiotic states of the gut microbiota in inflammatory bowel conditions and metabolic diseases [32, 33], which show age-related increases in incidence [34].

Prebiotic  $\beta(1-4)$  galacto-oligosaccharides (GOS) are complex carbohydrates that are resistant to digestion in the upper gastrointestinal tract. GOS arrive at the colon intact and consequently increase the abundance of specific primary and secondary degraders, resulting in an expanded probiome (beneficial members of the intestinal microbiota) [35]. GOS and fructo-oligosaccharides are the preferred prebiotics currently added to commercial infant formula to mimic the beneficial effects of the human milk oligosaccharides (HMOs) in breast milk [36]. Akkerman et al. [37] recently reviewed the effects of non-digestible carbohydrates in infant formulas as substituents of HMOs on the gut microbiota and maturation and stated that, beyond a well-established role in bifidogenesis, GOS also act as soluble decoy receptors to prevent adhesion of pathogens to epithelial cells, stimulate tight junctions, enhance intestinal barrier function through modulation of goblet cells [38], and reduce the release of the inflammatory marker CXCL8 by Caco-2 cells [39]. In addition, GOS support intestinal development in piglets, increasing the expression levels of  $\beta$ -defensins-2 and sIgA, suggesting improvement of mucosal immune responses [40]. In adults, increases in the abundance of *Bifidobacterium* upon GOS consumption have been reported in humans and animal models [41–45]. We demonstrated

that specific bifidobacteria (*B. longum*, *B. adolescentis*, *B. catenulatum*, and *B. breve*) increased when lactose-intolerant adults received purified GOS [46, 47]. We also demonstrated that pure GOS are capable of increasing the abundance of beneficial bacteria including *Faecalibacterium prausnitzii* and species of *Lactobacillus*, *Christensenellaceae*, *Collinsella*, *Prevotella*, and *Catenibacterium* [45, 47]. In addition, GOS directly induce the expression of *MUC2*, *TFF3*, and *RETNLB* in the colonic adenocarcinoma LS174T cell line, which exhibits a goblet cell-like phenotype [38]. Finally, studies in humans showed that GOS significantly increased the numbers of bifidobacteria, phagocytosis, NK cell activity, and anti-inflammatory IL-10 in healthy elderly individuals, with a significant reduction in the production of pro-inflammatory cytokines (IL-6, IL-1 $\beta$ , and tumor necrosis factor- $\alpha$ ) [48].

Based on the demonstrated effects of GOS on infants and adults, our study aimed to determine the impact of pure GOS [49] on the hallmarks of gut aging. We also evaluated the effect of short-term GOS feeding on how the aging gut microbiome responds to antibiotic challenges, since these interventions are common and relevant in older adults. In fact, in the years 2007 to 2009, patients aged  $\geq 65$  years used more antimicrobials, at 1.10 per person per year, compared to 0.88 antimicrobials used per person per year in patients aged 0–64 years [50]. Antibiotics induce gut microbiome disturbances, persistent through the constant presence in the food supply [51] or by introducing new and potentially stable changes with each cycle of antibiotic administration [52, 53]. Amidst these microbiota disturbances, the prevalence of infection by opportunistic pathogens, including *Clostridioides difficile*, is dramatically overrepresented in elderly populations [13]; thus, we evaluated if short-term GOS feeding influenced how the aging gut responded to the antibiotic challenges of a model of *Clostridioides difficile* infection to lay down the groundwork for future studies focused on prebiotics as preventive treatments against infection. Finally, we evaluated if colonic organoids [54] reproduced the in vivo response to GOS. Our findings add further evidence to previous limited studies on age-associated dysbiosis and intestinal physiology, providing valuable insights into how dietary GOS impact the microbiome composition and functionality, intestinal barrier function, and biomarkers of inflammation in an animal model of aging.

## Results

### Impact of GOS and antibiotics on the gut microbiome


A cohort of twenty-four young (6 weeks) and old (60 weeks) female C57BL/6J SPF mice ( $N = 48$ ) were fed the control diet for 20 days (microbiome normalization period) and then switched to the experimental diet containing prebiotics for an additional 2 weeks (Fig. 1a). Analysis of 16S

rRNA amplicon sequencing data performed on longitudinal time points 1 (T1, day 20, after normalization period), 2 (T2, day 35), 3 (T3, day 38), 4 (T4, day 42), and 5 (T5, day 50) assigned 190 distinct bacterial taxa, when the analysis was performed at the equivalent of species-level in QIIM E2.


Analysis of alpha diversity revealed a decrease in phylogenetic diversity in old and young animals receiving the prebiotics diet at T2, day 35 (repeated measures ANOVA with pairwise comparisons  $P < 0.05$ ) (Fig. 1b). Introduction of antibiotics at T3 reduced diversity in control-fed young and had a variable effect in old animals but had little impact on GOS-fed old mice. These antibiotic-driven changes in alpha diversity persisted through T4 and T5, revealing higher diversity in antibiotic-free, control-fed animals in both young and old animals. Animals did not lose weight during the antibiotic treatments. Likewise, none of the animals exhibited any signs of gastrointestinal distress or reduced activity before the clindamycin IP injection. After administration of clindamycin, mice exhibited temporary runny stools (T4).

Analysis of saccharolytic and non-saccharolytic bacteria (Fig. 1c) showed that GOS increased the relative abundance of mostly non-saccharolytic bacteria, driven by *Akkermansia*, (Figure S1), reducing the abundance of bacteria of undetermined metabolism at T2. These changes persisted through T5 in animals that were not treated with antibiotics, but additional shifts were observed in antibiotic-treated animals, increasing the abundance of saccharolytic taxa at T3–T4 with reductions in both non-saccharolytic and undetermined taxa. Although the bifidogenic effect of GOS has been previously reported by us and others [41, 45, 47, 55], we did not observe a consistently significant increase in the abundance of bifidobacteria in old or young animals fed GOS diet, also in accordance with previous reports of the responder-non-responder phenotype (Fig. 6a, left).

Principal coordinate analysis (PCoA) plots showed significant differences in microbiome composition between old and young mice prior to GOS treatment (ANOSIM  $R = 0.45$ ,  $P = 0.001$ , PERMANOVA pseudo- $F = 3.8$ ,  $P = 0.001$ ) at day 20 (T1) (Fig. 2a). We observed clustering of GOS-fed old and young mice (OG2 and YG2) away from control-fed animals and sub-clusters at T1 that separated control old and young animals. The separation between GOS and control clusters persisted in T2–T3, and sub-clustering was determined by the first antibiotic treatment. A more extreme effect of the antibiotics was observed in mice fed the control diet at T4 (Fig. 2c). At this time, the separation by diet persisted, but the clustering by age in the non-antibiotic control young and old mice was not observed. Finally, we observed



**Fig. 1** Prebiotic GOS and antibiotics decrease microbiome diversity in the gut. **(a)** Experimental design outlining time points T1 (post-standardization), T2 (post-specialized diet), T3 (post-antibiotics in water), T4 (post-clindamycin IP injection), and T5 (pre-sacrifice) ( $N = 48$ ) **(b)** Impact of the different treatments on phylogenetic diversity. GOS reduced diversity in both old and young animals. Alpha diversity declined with GOS consumption (T2) and antibiotic administration (T3, in young mice) and remained consistent through T5. **(c)** Relative abundance of saccharolytic, non-saccharolytic, and bacteria of undetermined metabolism over time. Line colors are as in Fig. 1b



**Fig. 2** Unweighted UniFrac PCoA plots and differences in the relative abundance of specific bacteria at different time points and treatments **(a)**. The T1–T2 PCoA plot (left) revealed the baseline differences between old and young mice (OC, old mice, control diet; OG, old mice, GOS diet; YC, young mice, control diet; YG, young mice, GOS diet). The middle panel shows the prebiotic impact on young (light purple) and old (pink) mice compared to the control diet (purple = young control, red = old control). The right panel shows the composed differences in relative abundances by age, diet, and time point. **b** The T2–T3 PCoA plot (left) and genus-level analysis (middle) showed the impact of the antibiotic treatment in water on both diet groups. Middle panel: control and GOS diets as before. Light blue dots represent no antibiotic treatment, and dark blue dots represent antibiotic treatment. **c** The T3–T4 PCoA plot (left) and genus-level analysis (middle) represent the samples immediately after clindamycin IP injection. The graphs did not show dramatic impacts to the microbiome, which were clearly visible in **d** the T4–T5 PCoA and taxa plots


clustering by diet and antibiotics at T5, with samples from both antibiotic treatments grouping together in the GOS animals but not control. These results indicate a clear influence of diet on the response of the microbial community to antibiotics. Analysis at the genus level identified 48 taxa significantly changed from T4 to T5 upon clindamycin injection in at least one of the groups in our analysis (Old\_control, Old\_GOS,

Young\_control, Young\_GOS) (Supplementary Text). Interestingly, while the antibiotic decreased the abundance of *Bifidobacterium* and *Lactobacillus* in young and old mice in both diets, clindamycin increased the relative abundance of non-saccharolytic bacteria in animals (young and old) receiving the control diet.

To investigate whether compositional differences were translated into potential functional discrepancies, we

conducted whole-genome shotgun (WGS) sequencing of stool collected from 6 old and 6 young animals (not treated with antibiotics) at time point 1 (control diet) and at time point 5 (GOS diet). First degraders encoding  $\beta$ -galactosidases and  $\beta$ -glucosidases metabolize GOS in the colon generating lactate and acetate [56]. In the healthy adult gut, secondary degraders including *Faecalibacterium* [57] and *Roseburia* [58] utilize these primary fermentation products to generate butyrate, which directly benefits host physiology [59–61]. The gene family output of HUMAnN2 identified 29 entries as  $\beta$ -galactosidases, the essential enzymes for the initial catabolism of GOS by primary degraders. Those included  $\beta$ -galactosidases (EC:3.2.1.23), phospho- $\beta$ -galactosidases (EC:3.2.1.85), and arabinogalactan endo-1,4-  $\beta$ -galactosidases (EC:3.2.1.89).  $\beta$ -galactosidases catalyze the hydrolysis of

terminal, non-reducing beta-D-galactoside residues, while phospho- $\beta$  galactosidases hydrolyze 6-phospho-  $\beta$ -D-galactoside residues. Arabinogalactan endo-1,4-  $\beta$ -galactosidases hydrolyze (1 $\rightarrow$ 4)- $\beta$ -D-galactosidic linkages in type I arabinogalactans. Clustering of relative abundance of  $\beta$ -galactosidases showed that most samples in the old control group had significantly (Kruskal-Wallis FDR corrected  $P < 0.05$ ) reduced abundance of unclassified  $\beta$ -galactosidases as well as  $\beta$ -galactosidases from *Bacteroides thetaiotaomicron* and *Akkermansia muciniphila*, abundance of which was increased in the old GOS group (Fig. 3a). Interestingly, most samples from control young and control old clustered within their own group, while GOS-fed mice (young and old) clustered mostly in one group. Figure 3b shows the box plots of representatives from *Bifidobacterium pseudolongum* (increased by GOS in



**Fig. 3 a** Whole-genome shotgun (WGS) sequencing of stool samples showed that GOS treatment significantly modified the abundance of 22 out of 29 of beta-galactosidases in old and young mice (\*Kruskal-Wallis FDR-corrected  $P < 0.05$ ). **b** Representative patterns of abundance of beta-galactosidases from *B. pseudolongum*, *L. johnsonii*, and *E. faecalis*

both young and old animals), *Lactobacillus johnsonii* (only increased by GOS in young animals), and *Enterococcus faecalis* (overrepresented in the old control group) that had low read counts, and hence, their pattern of representation could not be clearly assessed from the heatmap.

### GOS impact on intestinal permeability, biomarkers of inflammation, and mucin production

Assessment of gut barrier function showed significantly increased intestinal permeability in old compared to young mice, with decreased values in old animals fed GOS (Fig. 4a(i)). No significant differences were observed between control and GOS diets in young animals. GOS diet increased the mucus abundance and thickness in the lumen of old mice ( $2 \times 2$  ANOVA  $P < 0.005$ ) (Fig. 4a(iii)), but a less pronounced effect was observed in young animals. Imaging analysis of PAS-stained colon tissues using the ImageJ software confirmed the increased abundance of mucin/mucin-producing cells (blue/purple) in the old GOS group compared to all of the other groups (Figure S2).

Epithelial surface integrity is maintained in part by genes in the trefoil factor (TFF) family including TFF3 [62]. TFF3 binds to the cysteine-rich amino terminal von Willebrand factor (vWF) of MUC2 enhancing the protection of the gastrointestinal mucosa against injury through interactions with mucins [63]. The resistin-like molecule (RELM) family of proteins facilitate the formation of unique disulfide-dependent multimeric assembly units. RELM $\beta$  is predominantly expressed by goblet cells and epithelial cells in the colon and is involved in the maintenance of colonic epithelial barrier function by upregulating MUC2 [64]. The expression of MUC2 was increased with GOS, while RELM $\beta$  and TFF3 showed non-significant increases (Fig. 4a(ii)).


Increased levels of circulating cytokines (plasma and serum) associated with aging have been reported in humans and mice [28, 65, 66]. In our study, the most important factor in modulating levels of serum cytokines was antibiotic administration ( $2 \times 2 \times 2$  ANOVA  $P < 0.05$ ). Overall, the antibiotics groups had higher IL-17 and IL-6 levels in both control and GOS diets. Within the antibiotics groups, the levels of IL-6 were higher in the GOS diet groups, regardless of age, and higher in the old compared to young animals in the control diet groups (Fig. 4b(iii and iv)). Antibiotic administration resulted in higher IP-10 and eotaxin in the control diet groups and lower IP-10 and eotaxin in the GOS diet groups (Fig. 4b(i and v)). Young animals had higher levels of IL-13, regardless of diet and antibiotics (Fig. 4b(ii)). Finally, although the levels of serum tumor necrosis factor (TNF) $\alpha$  did not show significant differences between the groups (not shown), RTqPCR analysis revealed significantly increased gene expression of TNF $\alpha$  in distal colon tissue of

old mice, and prebiotics decreased the expression of the cytokine (Fig. 4b(vi)).

### Colon mucosa transcriptome profiling showed significant differences in response to GOS diet between young and old mice

We next aimed to determine whether GOS induced similar changes in colon gene expression in young compared to old animals. Covariate analysis of transcriptomics data from colon tissue of 6- versus 60-week-old mice fed the control or GOS diets showed clear patterns of gene expression in pairwise group comparisons (Fig. 5, Supplementary Table 1). Old animals fed GOS had an increased representation of genes involved in the production of molecular mediators of the immune response (GO:0002440) compared to old animals fed the control diet. Functions included immunoglobulin production, positive regulation of T-helper 1 cell cytokine production, and positive regulation of immunoglobulin biosynthetic processes. Conversely, old animals fed GOS had a lower expression of genes in the collagen-containing extracellular matrix (GO:0062023), specifically a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, collagen, type VI, alpha 1, fibronectin 1, and insulin-like growth factor binding protein 6 (Fig. 5a).

The majority of genes (92 genes) overexpressed in young compared to old animals fed the prebiotics diet were functionally associated with binding (GO:0005488), specifically protein binding (GO:0005515, 64 genes), ion binding (GO:0043167, 53 genes), and protein-containing complex binding (GO:0044877, 20 genes) (Fig. 5b). In old animals fed GOS, genes involved in small molecule metabolic processes (GO:0044281) and specifically the respirasome (GO:0070469) were overexpressed compared to young animals on the same diet (Fig. 5). In young mice, GOS also stimulated the expression of the galectin gene *Lgals1*, which encodes a  $\beta$ -galactosyl-binding lectin that bridges molecules by their sugar moieties, forming a signaling and adhesion network [69]. Galectins bind specifically to  $\beta$ -galactoside sugars and have been linked to host-microbe interactions by direct binding to microorganisms affecting their survival or function and modulating the innate or adaptive responses of immune cells against microbes either via extra- or intracellular mode of action. In fact, galectins can have direct antimicrobial effects [70]. Accordingly, further analysis of gene expression differences by mapping onto the Kyoto Encyclopedia of Genes and Genomes (KEGG) metabolic maps ([www.genome.jp/kegg/](http://www.genome.jp/kegg/)) showed higher expression levels of genes in focal adhesion, PI3K-Akt, and ECM-receptor interaction pathways [71] in young compared to old animals. The lowest expressed gene in both old and young animals fed GOS was *Trpv6* (transient receptor potential cation channel, subfamily V, member 6), a highly selective calcium channel that acts via calcium



**Fig. 4** (See legend on next page.)



(See figure on previous page.)

**Fig. 4 a** (i) Old mice had higher intestinal permeability measured by FITC-dextran assays than young animals. (ii) Old mice fed GOS had significantly increased *MUC2* expression (\* $p < 0.05$ ). The expression of *TFF3* and *RELMb* tended to increase in the GOS groups, but differences were not statistically significant. (iii) Paraformaldehyde vapor fixation and subsequent PAS staining showed increased mucus thickness in old mice fed the prebiotics diet. **b** Inflammatory biomarkers were modulated by antibiotics and GOS. A  $2 \times 2 \times 2$  ANOVA test showed (i) increased serum IP-10 in GOS-fed animals without antibiotic treatment and in antibiotic-treated animals fed control diet. (ii) Serum IL-13 levels were higher in young animals than in old animals in all groups. (iii) IL-17 levels were higher in antibiotic-treated animals than in animals without antibiotics. (iv) IL-6 was increased in antibiotic-treated old animals (GOS and control) compared to old animals without antibiotic treatments and elevated in young animals treated with both GOS and antibiotics. (v) Eotaxin levels were higher in GOS-fed animals without antibiotic treatment, but lower in GOS-fed animals that received antibiotics, regardless of age. (vi) Expression of TNF $\alpha$  quantified by RT-qPCR was higher in old animals compared to young and reduced by GOS treatment in old animals


absorption in the intestine and kidney [72]. This gene was overexpressed in young compared to old animals both on the GOS and control diets.

**Responders versus non-responders to GOS diets**


It has been previously reported that, when fed GOS, a proportion of individuals will not mount a bifidogenic response [41, 45, 47], i.e., they will not display an appreciable increase in the relative abundance of bifidobacteria. In this study, we injected stools from responder and non-responder mice into colon organoids derived from a single young C57BL/6J animal to determine if, by using organoids derived from primary tissue from a single animal colonized with stools from multiple mice and treatments, we were capable of reproducing the bifidogenic response-no response effect observed in vivo. Stools from individual mice were processed, mixed with either GOS or PBS (control), and injected into organoids derived from the colon as previously described [73]. Organoids were collected immediately following injection, and at 24 and 72 h after injection for 16S rRNA amplicon

sequencing and quantitative PCR analysis. Both, sequencing (Fig. 6a) and qPCR data (Fig. 6b) showed that the response (continuous lines in the figure) and non-response (represented as dashed lines) phenotypes were reproduced in the organoids injected with stools from both old and young mice, albeit the response was less pronounced in organoids injected with stools from old animals compared to young. Shannon diversity index and species richness values showed a rapid reduction soon after injection (Fig. 6c), with no statistically significant differences between treatments (GOS or PBS) or between young and old samples at any time (except at baseline) in contrast with the GOS diversity decrease observed in vivo. Principal coordinate analysis (PCoA) of samples showed compositional significant differences between the groups by age (PERM ANOVA  $P$  value = 0.01) and time ( $P = 0.02$ ), while the overall differences in microbiome composition between PBS and GOS-treated organoids approached significance ( $P = 0.06$ , not shown) (Fig. 6d).

At the compositional level, we observed clear differences between the original stool samples processed for



**Fig. 5** STRING network analysis [67] of expression data from colon showed different GOS effects on the intestinal epithelium of old and young mice. **a** GOS induced expression of binding-related genes (GO:0005488) in young mice while inducing **b** small-molecule metabolic processes genes (GO:0044281) in old animals. Network nodes represent predicted proteins. Splice isoforms or post-translational modifications are collapsed so each node represents all the proteins produced by a single, protein-coding gene locus. The confidence cutoff for showing interaction links was 0.900 (highest). The lower panel in **a** shows the most represented GO categories within binding-related genes in our transcriptomics data. **c** A heatmap of expression data revealed that GOS act as a modulator of the immune system in old and young mice. The heatmap was generated using ClustVis [68]. Rows were centered; unit variance scaling was applied to rows. Rows were clustered using correlation distance and average linkage



**Fig. 6** The variable bifidogenic effect observed in vivo was reproduced in vitro in the organoid platform as shown by **a** 16S rRNA amplicon sequencing and **b** high-throughput qPCR. **c** Shannon diversity and species richness within microbiota-colonized organoids declined over time. **d** Unweighted UniFrac PCoA plots revealed differences between old and young microbiota upon colonization in organoids, which converged to a single grouping over 72 h. **e** Taxonomy plots of microbiota-colonized organoids showed changes over time in communities derived from both old and young animals

injection, the microbiome of organoids injected with young versus old samples, and between the different treatments (GOS and PBS) (Supplementary Figures 3 and 4, and Supplementary Text). Our analysis allowed us to identify bacterial groups especially sensitive to manipulation, which were eliminated from the stool sample upon processing for injection into the organoids,

potentially creating the niche for expansion of groups originally in very low numbers.

**Discussion**

Our study confirmed previous reports indicating increased intestinal permeability (a “leaky gut”) during aging [19, 28]. Consistent with previously reported data [17], old

mice had a distinct microbiome, increased ratios of non-saccharolytic versus saccharolytic bacteria, and correspondingly, lower abundance of  $\beta$ -galactosidases (EC: 3.2.1.23), phospho- $\beta$ -galactosidases (EC:3.2.1.85), and arabinogalactan endo-1,4- $\beta$ -galactosidases (EC: 3.2.1.89). Based on numerous studies detailing the beneficial effects of prebiotic GOS, which include modulation of the gut microbiome with specific increases in beneficial bacteria [45, 47], stimulation of tight junctions and enhancement of the intestinal barrier function through modulation of goblet cells [38], reduction of inflammatory markers release in cell culture models [39], support of intestinal development and mucosal immune responses [40], and reduction in adherence of enteropathogenic *Escherichia coli* to tissue culture cells [74], we designed a short-term feeding trial to determine the effects of GOS on the aging gut microbiome and gut homeostasis. Our study also aimed to assess the transient effects of GOS on gut responses to antibiotic administration.

In contrast with a previous report [17], old animals had a significantly higher abundance of *Akkermansia. A. muciniphila* has been shown to reduce inflammation [75] and improve intestinal barrier integrity [76] suggesting that controlled mucolytic activity could benefit host physiology. However, uncontrolled degradation of mucins by proteolytic bacteria can increase inflammation, damage the barrier integrity, and increase susceptibility to pathogen infection [28, 77]. Old mice had a lower representation of *Bacteroides*. Although highly variable, the abundance of *Bacteroides* in aging human individuals is also lower than in the adult population [78]. GOS had a clear impact on the composition of the gut microbiome, increasing mostly the abundance of non-saccharolytic bacteria (*A. muciniphila*) but also saccharolytic species (genus *Bacteroides*, unknown species of the order *Bacteroidales*, and species of *Lactobacillus*). It has been previously reported that dietary GOS increased the abundance of bifidobacteria in human adults [41, 47] and older adults [55]. We also showed that GOS induced a variable bifidogenic response in 8–12-week-old mice [45]. In this study, we did not observe a consistent significant increase in the abundance of bifidobacteria in old or young animals fed the GOS diet. However, old mice did have a reduced proportion of bacterial  $\beta$ -galactosidases (EC:3.2.1.23), suggesting a reduction in metabolic potential of the microbiota. When fed GOS diet, both old and young animals showed an increased abundance of  $\beta$ -galactosidases. Reduced abundance of intestinal saccharolytic enzymes in the aging gut has been reported (although data is not conclusive) [79, 80] and may have important nutritional implications for the digestion of dietary carbohydrates by elderly individuals.

Administration of the GOS diet reduced bacterial diversity significantly in young and old mice. This is in

accordance with the studies of GOS-supplemented infant formula [81] and in contrast with previous studies on human adults [47, 82] and young or adult BALB/c mice that showed no effect of GOS on bacterial diversity [83, 84]. Alpha diversity further decreased in young animals after administration of the antibiotic cocktail in the drinking water and remained stable throughout the remaining course of the study. The antibiotic treatment was selected based on the regime used in the murine model of *C. difficile* infection developed by Chen et al. [85] and includes an initial antibiotic cocktail in the drinking water that contains kanamycin, gentamicin, colistin, metronidazole, and vancomycin at a sufficient dose to disrupt the microbiome and increase the susceptibility to infection without major side effects. Reikvam et al. [86] reported that mice refrained from drinking metronidazole in water and lost weight under such treatment, possibly due to the concomitant reduction in food intake; however, in our study, animals did not lose weight during the antibiotic treatments. Likewise, none of the animals exhibited any signs of gastrointestinal distress or reduced activity before the clindamycin IP injection with temporary runny stools after the administration of the second antibiotic.

Clindamycin, depending on the organism, infection site, and concentration, can act as a bacteriostatic or bactericidal antibiotic. This antibiotic prevents the formation of peptide bonds effectively inhibiting protein synthesis by binding to the 50S ribosomal subunit. Clindamycin palmitate is hydrolyzed in the gastrointestinal tract and then distributed across the body [87]. This antibiotic has been associated with a high incidence of antibiotic-associated diarrhea [88]. In our study, the antibiotic caused an expected decreased abundance of *Bifidobacterium* in young and old mice on both diets. This is in agreement with a previous in vitro report that showed that, in contrast with the antibiotics tetracycline and ciprofloxacin, GOS feeding after clindamycin administration did not result in increased abundance or recovery of bifidobacteria populations [89].

Transcriptomics analysis of the colon at the end of the experiment indicated that GOS impacted intestinal expression differently in young compared to old mice. This differential modulation of host gene expression likely plays a critical role in the differences observed in host physiology, as well as in differential modulation of the microbiota composition. Old animals fed the GOS diet had increased expression of genes involved in small molecule metabolic processes (GO:0044281) and specifically the respirasome (GO:0070469). Although the role of these respiratory enzymes organized into supercomplexes in the intestine has not been defined, it could be hypothesized that they would reduce oxidative damage increasing metabolism efficiency [90, 91].

The effect of GOS on colonic gene expression of young mice showed a significant enrichment in binding-related genes (GO:0005488). Our study reports for the first time the specific *in vivo* induction of the galectin gene *Lgals1*, a  $\beta$ -galactosyl-binding lectin that bridge molecules by their sugar moieties, forming a signaling and adhesion network [69] by GOS diet. Previous studies showed that dietary supplementation with a mixture of short-chain GOS and long-chain fructo-oligosaccharides (lcFOS) in a 9:1 ratio could be involved in the maturation of the immune response in infants and induction of oral tolerance, hence reducing the risk of developing an allergic disease [92]. Likewise, this prebiotic mix suppressed the development of acute allergic symptoms, possibly by inducing regulatory T cells [93, 94]. The exact mechanisms of these effects are not known; however, a study suggested that prebiotics could modulate the immune response through galectins [95]. Intestinal epithelial cells are crucial in maintaining homeostasis and directing mucosal immune responses. They express Toll-like and Nod-like receptors that recognize antigens present in the intestinal lumen. When the Toll-like receptors are activated, intestinal epithelial cells contribute to the modulation of immune responses by secreting soluble mediators that bridge luminal signals with the immunological tissues. Both antigen-presenting cells and intestinal epithelial cells express proteins involved in the recognition of carbohydrate (glycan) structures present on bacterial and dietary components or glycosylated membrane proteins expressed by other cell types. Galectin-1 in particular have anti-inflammatory properties by enhancing the expansion and IL-10 production of regulatory T cells, resulting in the suppression of pro-inflammatory cytokines, including IFN- $\gamma$  and TNF- $\alpha$  by effector T cells [96, 97]. Further analysis showed higher expression levels of genes in focal adhesion, PI3K-Akt, and ECM-receptor interaction pathways [71]. Cell-matrix adhesions play essential roles in cell motility, cell proliferation, cell differentiation, regulation of gene expression, and cell survival. At the cell-extracellular matrix contact points, specialized structures (focal adhesions), collections of actin filaments anchored to transmembrane receptors of the integrin family through a multi-molecular complex of junctional plaque proteins, act as structural links between membrane receptors and the actin cytoskeleton, or as signaling molecules, including different protein kinases and phosphatases, their substrates, and various adapter proteins [98, 99].

Microbiome research using colonic organoids as an *in vitro* platform is at its infancy [54, 100]. In this study, we took advantage of this platform to determine if the bifidogenic responder-non-responder phenotype [41, 45, 47] could be replicated *in vitro*. Injections of stools showed that the responder and non-responder

phenotypes were reproduced in the organoids injected with stools from old and young mice. This allowed us to speculate that the primary contributor to the phenotype is the presence or absence of specific taxa and specific genetic components of the microbiota. Stool-injected organoids showed a rapid decrease in bacterial diversity after injection and showed compositional significant differences between the groups by age of the donor animal, time post-injection, and GOS treatment. This rapid decline in microbial diversity post-injection is likely due in part to oxygen exposure and limited nutrients; however, it may also be a consequence of the absence of host factors that facilitate microbial growth and colonization. In our study, the principal contributor to changes in the composition of the injected organoids was time. However, the differences in the microbiome associated with age were maintained over time, and minor differences attributable to the prebiotics were observed. This suggests that it could be possible to modify the experimental design to detect biologically relevant microbiome differences induced by treatment. The analysis of microbiome composition over time allowed us to identify bacterial groups especially sensitive to manipulation that were radically eliminated from the stool sample upon processing for injection into the organoids, creating a niche for expansion of groups originally in very low numbers in the stool samples. It could be argued that the differences in abundances of those bacterial groups help to explain the differences in the GOS bifidogenic response *in vivo*; however, the perturbation associated with the preparation of stool samples for injection into organoids was substantial causing the sharp decline in bacteria sensitive to such manipulations. Intestinal communities are unlikely to experience such disruptions naturally, and hence, it seems unlikely that the bacteria reduced by manipulation for organoid injection play a role in bifidogenic response *in vivo*.

The most remarkable effect of prebiotics in the old animals was the reduction of intestinal permeability and increased mucus biosynthesis. Defects in the intestinal barrier associated with aging have been previously reported [101, 102]. A relevant study by Thevaranjan et al. [28] reported that intestinal permeability increased with age due to age-associated microbial dysbiosis. In their study, increased permeability led to increased systemic inflammation with high levels of serum IL-6. In our study, we observed statistically non-significant increased IL-6 levels in the old control mice that were given antibiotics, but not in the non-antibiotics group. IL-6 were further increased in both young and old animals in the antibiotics-GOS groups. Increased serum IL-6 has been reported in neonate mice upon administration of antibiotics [103]. Although more studies are needed, we could speculate that the effect of GOS potentiated the impact

of antibiotics, in both cases through modulation of the gut microbiome.

## Conclusions

Our study showed that dietary GOS modulated homeostasis of the aging gut by promoting changes in the microbiome composition and host gene expression, which was translated into decreased intestinal permeability and increased mucus production. It is not clear from this study if such modulation occurred by direct GOS-host interactions or exclusively via modulation of the microbiome. This study also demonstrated that age is a deciding factor on how prebiotics impact the microbiome and expression of intestinal epithelial cells. This was especially evident from the induction of the galectin-1 gene in young but not old mice, which has incredible implications on the modulation of the immune response. The present study did not attempt to correlate the transcriptome to differences in the microbiome; however, future studies will elucidate the complex interactions occurring during modulation of the host-microbes ecosystem by prebiotics.

## Methods

### Animal housing, treatment, and sample collection

Forty-eight female C57BL/6J SPF mice (24 6-week-old and 24 60-week-old) received a control diet (D17121301; Research Diets INC.) for a 2-week co-housed (6/cage) normalization period. Animals were subsequently paired off (1 old/1 young) from different normalization cages and separated into groups fed control or GOS diets, using an optimized GOS diet (D17121302; Research Diets INC.) replacing 71.8 g of cellulose with 71.8 g of pure GOS per kilogram. Pure prebiotics were generated by heterologous expression of the beta-hexosyl transferase from *Sporobolomyces singularis* in *Pichia pastoris* as previously described [45, 49]. After 2 weeks, half of the animals in each group (6 young and 6 old from each diet) were administered an antibiotic cocktail in their drinking water for 3 days according to the *C. difficile* infection protocol described by Chen et al. [85]. The cocktail contained kanamycin (40 mg/kg), gentamycin (3.5 mg/kg), colistin (4.2 mg/kg), metronidazole (21.5 mg/kg), and vancomycin (4.5 mg/kg). The concentrations of antibiotics in water were calculated based on the average weight and expected water consumption of mice. After 3 days, the water was replaced with antibiotic-free water, and the animals were allowed 2 days to recover prior to receiving an intraperitoneal injection of clindamycin (10 µg/g body weight). Animals remained on their respective diets and were sacrificed following a 1-week recovery period. For both experiments, fresh stool samples were collected and stored at -80 °C. Intestinal tissues and contents were collected at

termination (Fig. 2a). Animal weight and behavior were monitored throughout the study.

### Mouse intestinal permeability assay

Mice were administered 100 mg fluorescein isothiocyanate (FITC) dextran/100 g body weight via oral gavage 4 h prior to sacrifice. Immediately following euthanasia, blood was harvested via cardiac puncture, and the serum was subsequently separated via centrifugation. The serum from each animal was assayed for the presence and quantity of FITC signal with a TECAN Infinite M200 plate reader, using an excitation wavelength of 485 nm and an emission wavelength of 528 nm. A standard curve of FITC dextran was used to quantify the signal in each serum sample.

### Mucin staining and tissue imaging

The sections of mouse distal colon were harvested, embedded in optimal cutting temperature (OCT) compounding agent, and flash-frozen in a dry ice-filled ethanol bath without fixation. Blocks were stored at -80 °C until cut at -20 °C on a cryostat, and frozen sections were mounted onto slides. The sections were immediately subject to paraformaldehyde vapor fixation (4% PFA, 60C) for 8 h prior to PAS staining and subsequent imaging on Nikon 2000-E inverted widefield microscope. Images were saved as RFG files and uploaded to the ImageJ Analysis software, where pixel analysis was performed to quantify the abundance of mucin/mucin-producing cells (blue/purple) and epithelial cells (pink).

### Organoid cultivation and colonization

Organoids were derived from colon crypts harvested from a single young C57BL/6J and grown in 96-well plates embedded in Corning® Matrigel® matrix (Corning Inc., Corning NY) and overlaid with complex DMEM-F12 growth media containing 1 µg/ml Pen Strep [104, 105]. Organoids were incubated at 37 °C under 5% CO<sub>2</sub> and ambient oxygen and were passaged into new plates every 10–14 days. Organoids used for injection were grown 4 days post-passage and were uniform in size and shape. Homogenized stool samples collected from both young and old donor mice prior to GOS treatment were filtered through 5-µM syringe filters (Millipore) and loaded into microinjection needles for organoid inoculation as previously described [54]. Loaded needles were attached to the injection apparatus, and organoids were injected with ~400 pL of stool suspension. Injected organoids were then incubated at 37 °C under 5% CO<sub>2</sub> and ambient oxygen with supplemental antibiotics. Organoids were harvested at 0 h, 24 h, and 72 h post-injection.

### Nucleic acid isolation

DNA from fecal samples and microbiota-colonized organoids were extracted using the Qiagen DNeasy stool DNA isolation kit (Qiagen, Valencia, CA) with an additional bead-beating step aimed to ensure uniform lysis of bacterial spores. Samples were loaded into tubes containing 10 mg of sterile, acid washed, 1  $\mu$ m glass beads, and homogenized for 5 min at 15 Hz in Qiagen TissueLyser II (Qiagen, Valencia, CA). DNA was subsequently used for 16S rRNA amplicon sequencing and whole-genome shotgun sequencing. RNA isolation from tissues was performed using the Qiagen RNeasy kit (Qiagen, Valencia, CA) following the manufacturer's instructions for subsequent use in RTqPCR and mRNA sequencing.

### High-throughput quantitative PCR detection of *Bifidobacterium*

The Access array AA 24.192 (Fluidigm Corporation, San Francisco, CA) was used in the UNC Advanced Analytics Core. Primers for amplification of the 16S rRNA gene and GroEL have been validated in previous studies [106–109]. The taxonomic groups targeted in the *Bifidobacterium* array include domain *Bacteria*, phylum *Actinobacteria*, genus *Bifidobacterium*, and *Bifidobacterium* species. Pre-amplification (specific target amplification (STA)) assays and microfluidic qPCR were performed on a BioMark HD reader as described [45]. Raw data were normalized using the Livak method [110]. Cq values for each sample were normalized against their respective Cq value obtained from universal primers using the equation: ratio (reference/target) =  $2^{-Ct_{(ref)} - Ct_{(target)}}$ .

### 16S rRNA amplicon sequencing

Total DNA was subject to amplification of the V4 region of the 16S rRNA gene using primers (515F-806R) with Illumina adaptors. Amplicons were barcoded using Illumina dual-index barcodes (Index 1(i7) and Index 2(i5)), purified using Agencourt® AMPure® XP Reagent (Beckman Coulter, Brea, CA) and quantified with Quant-iT™ PicoGreen® dsDNA Reagent (Molecular Probes, Thermo Fisher Scientific, Waltham, MA). Libraries were pooled in equimolar amounts and sequenced on MiSeq (Illumina, San Diego, CA).

### Data analysis

Sequencing output from the Illumina MiSeq platform was converted to fastq format and demultiplexed using Illumina Bcl2Fastq 2.18.0.12. The resulting paired-end reads were processed using QIIME 2 [111] 2018.11. Index and linker primer sequences were trimmed using the QIIME 2 invocation of cutadapt. The resulting paired-end reads were processed with DADA2 through QIIME 2 including merging paired ends, quality filtering, error correction, and chimera detection. An average of 81,904

filtered, denoised, merged, non-chimeric sequences were produced per sample. Amplicon sequencing units from DADA2 were assigned taxonomic identifiers using Green Genes release 13\_08. Alpha diversity indexes (Faith PD whole tree, EVENNESS (Shannon), and observed species) were estimated using QIIME 2 at a rarefaction depth of 10,000 sequences per sample. Beta diversity estimates were calculated within QIIME 2 using weighted and unweighted UniFrac distances as well as Bray-Curtis dissimilarity between samples at an initial subsampling depth of 5000 and then 1000 since antibiotic-treated samples had lower yields than non-antibiotic samples. The results were summarized and visualized through principal coordinate analysis, and significance was estimated as implemented in QIIME 2. Significance of differential abundance was estimated using ANCOM as implemented in QIIME 2.

### Assignment of saccharolytic (SAC) and non-saccharolytic (NON\_SAC) to bacterial taxa

We used the reference study by Vieira-Silva et al. [112], which mined 532 publicly available gut reference genomes and assigned them to four different groups (proteolytic, saccharolytic, lipolytic, and generalist bacteria) using metagenome analytical methods, and the study by Magnusdottir et al. [113] on the metabolic reconstruction network AGORA. In the case that the genus was not categorized in the mentioned studies, we referred to the *Bergey's Manual of Systematic Bacteriology* [114] and previously published reports when the genus was not found in either source [115–126]. We included saccharolytic and generalist bacteria in the SAC group, as well as chemolithoheterotrophic bacteria capable of using either carbohydrates or the metabolites derived from carbohydrate sources (for example, *Dehalobacter*, *Geobacillus*). Likewise, the NON\_SAC category included proteolytic and lipolytic bacteria.

### Whole-Genome Shotgun (WGS) sequencing

One nanogram of intact genomic DNA was processed using the Nextera XT DNA Sample Preparation Kit (Illumina, San Diego, CA). In this process, the target DNA was simultaneously fragmented and tagged by the Nextera Enzyme Mix containing transposome, which fragments the input DNA and adds bridge PCR (bPCR)-compatible adaptors required for binding and clustering on the flow cell. Next, fragmented DNA was amplified via a limited-cycle PCR program adding index 1(i7) and index 2(i5) (Illumina) in a unique combination for each sample, as well as primer sequences required for cluster formation. Libraries were purified using Agencourt® AMPure® XP Reagent (Beckman Coulter, Brea, CA) and quantified with Quant-iT™ PicoGreen® dsDNA Reagent (Molecular Probes, Thermo Fisher Scientific, Waltham, MA). All libraries were pooled in equimolar amounts and

heat-denatured before loading on Illumina HiSeq2000 Rapid.

#### Data analysis

Sequencing output from the Illumina platform was converted to fastq format and demultiplexed using Illumina Bcl2Fastq 2.18.0.12. An average of 11 million reads was generated per sample. Quality control of the demultiplexed sequencing reads was verified by FastQC. The resulting paired-end reads were aligned with Bowtie2 [127] against the host reference, and all aligning reads will be eliminated. Paired-end reads were joined with vsearch 1.10.2. The resulting single-end reads were again aligned against the reference with Bowtie2 retaining all reads that did not align. Estimates of taxonomic composition, gene family, path abundance, and path coverage were produced from the remaining reads using HUMAnN2 [128].

#### Reverse transcription qPCR

1.5 µg of total RNA was subject to reverse transcription using the iScript Advanced cDNA synthesis kit (Bio-Rad, Hercules, CA). Total nucleic acid was subsequently quantified and normalized to 1 ng/µl prior to qPCR setup. qPCR reactions were performed using the PowerSYBR Green Master Mix, 3 ng of total nucleic acid per reaction, and the following primer pairs (at a final concentration of 100 nM): TNFα (Fwd: 5'-ACGGCATGGA TCTCAAAGAC-3', Rev: 5'-GTGGGTGAGGAGCACG TAGT-3') [129], IL-6 (Fwd: 5'-CTGCAAGAGACTTC CATCCAGTT-3', Rev: 5'-GAAGTAGGGAAGGCCG TGG-3') [130], GapDH (Fwd: 5'-TGCACCACCACCAA CTGCTTAG-3', Rev: 5'-GGATGCAGGGATGATGTT C-3') [131], Muc2 (Fwd: 5'-GCTGACGAGTGGTTGG TGAATG-3', Rev: 5'-GATGAGGTGGCAGACAGG AGAC-3') [132], RELMβ (Fwd: 5'-CCATTTCTTG AGCTTTCTGG-3', Rev: 5'-AGCACATCCAGTGACA ACCA-3') [133], and TFF3 (Fwd: 5'-CAGATTACGT TGGCCTGTCTCC-3', Rev: 5'-ATGCTTGCTACCCT TGGACCAC-3') [133]. qPCR reactions were performed on the QuantStudio Q6 instrument (Thermo Fisher Scientific, Waltham, MA). The samples were run in technical triplicate, and included no template, and no reverse transcriptase controls in addition to the internal GapDH control for normalization of gene expression. Cycle threshold values (CT) were calculated from amplification plot data by the QuantStudio6 software at the completion of each qPCR run. CT values were normalized to the internal GapDH controls to generate ΔCT values for each gene in each animal. ΔΔCT values were generated by comparing the ΔCT values from control animals within an age group to the ΔCT values from experimental animals within that same group. Fold change (FC) of gene expression of each target gene between groups

was calculated by using the following equation:  $FC = 2^{(-\Delta\Delta CT)}$ .

#### Mouse mRNA sequencing

Total RNA isolated from mouse colon was processed using the NuGEN Universal Plus mRNA-Seq kit (NuGEN Technologies, Inc., San Carlos, CA) for whole transcriptome sequencing as directed by the manufacturer. Briefly, total RNA was subject to poly(A) selection, fragmentation, first-strand synthesis, second-strand synthesis, end repair, adaptor ligation, strand selection, and finally library amplification. Indexed cDNA libraries quantified via Quant-iT™ PicoGreen® dsDNA reagent (Thermo Fisher Scientific, Waltham, MA) were pooled at equimolar concentrations and sequenced on Illumina HiSeq4000 platform.

#### Data analysis

Demultiplexed paired-end reads from mRNA sequencing experiments were aligned with STAR [134] against the mouse Mm9 reference. Salmon [135] was applied to the resulting alignment to estimate the quantity of transcript expression. The significance of differential expression was measured with DESeq2 [136].

#### Cytokine analysis

Serum was subject to Milliplex cytokine/chemokine assay MCYTOMAG-70K (Millipore, Sigma, Burlington, MA) for the detection and quantification of TNFα, IP-10, IL-17, IL-13, IL-10, IL-6, IL-4, IL-1α, eotaxin, IL-12, and IL-7. The assay was run at the UNC Advanced Analytics Core on DropArray™96 Plate system (Curiox Biosystems, San Carlos, CA) as recommended by the manufacturer.

#### Statistical analyses

Group differences were tested for statistical significance using ANOVA with ad hoc Tukey tests for pairwise comparisons, and *P* values were reported accordingly. Differences in the microbiota composition were determined using non-parametric tests (Kruskal-Wallis or Mann-Whitney as appropriate) and analysis of composition of microbiomes (ANCOM) [137] analyses. FDR correction was applied to the statistical analysis of samples to take into consideration multiple comparisons. Differences in beta diversity were determined using analysis of similarity (ANOSIM) and permutational multivariate analysis of variance (PERMANOVA) analyses in QIIME2. Statistical differences in the relative abundance of beta-galactosidases were determined using the Kruskal-Wallis *H* test with FDR correction in STAMP [138]. Unless otherwise indicated, the cutoff for statistical significance was set to *P* < 0.05 for the determination of differences between the groups in the microbiota, gene expression, intestinal permeability, and cytokine analyses.

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s40168-020-00980-0>.

**Additional file 1: Figure S1.** Relative abundance of *Bacteroides* (a), *Akkermansia muciniphila* (b), and *Lactobacillus* (c) were increased by GOS diets. Abundance of *Clostridium* (d), *Adlecreutzia* (e) and *Ruminococcus* (f) were reduced by GOS diets.

**Additional file 2: Figure S2.** Individual pixel-pigment analysis of mucus staining of tissue samples revealed a distinctly higher abundance of pixels in the lower range of the pigment spectrum (darker colors, blue and purple) in GOS-fed old animals, compared to young or control-fed old animals (a). Pigment-specific histograms of the RGB image files were generated using ImageJ software, revealing differences between samples in the abundance of pixels in each image, as well as providing quantification of pixels within each pigment range (b). Ratios between epithelial and mucosal pixels were calculated and used in determining the fold change in pigment between specific pairs of animals, Old animals GOS vs Control diets, Young animals GOS vs Control diets, Old animals vs Young animals feeding on control diet, and finally Old animals vs Young animals feeding on GOS diet (c). Mucus fold change was calculated for each animal compared to Young animals fed control diet (d).

**Additional file 3: Figure S3.** Heatmap represents changes in bacterial abundance within old microbiota-colonized organoids over time when supplemented with either PBS (control), GOS, or Lactose.

**Additional file 4: Figure S4.** Heatmap represents changes in bacterial abundance within young microbiota-colonized organoids over time when supplemented with either PBS (control), GOS, or Lactose.

**Additional file 5.** Supplementary text.

**Additional file 6: Table S1.** Diet composition as provided by the manufacturers.

**Additional file 7: Table S2.** Expression data from colons of young and old mice fed either the control or GOS diets.

## Acknowledgements

Thank you to Dr. Natasha Snyder's Lab, especially Rachel Battaglia for the assistance with mouse tissue harvest.

## Authors' contributions

Conceptualization: J.A., and M.A.A.-P. Methodology: J.A., M.A.A.-P., S.M., and S.F. Formal analysis: J.A., M.A.A.-P., and J.R. Investigation: J.A. and S.F. Resources: E.M., S.D., E.B., S.M., R.T., J.M.B., and M.A.A.-P. Data curation: J.A., S.F., and J.R. Writing—original draft: J.A. and M.A.A.-P. Writing—review and editing: J.A., M.A.A.-P., R.T., S.F., J.M.B., and J.R. Visualization: J.A. and M.A.A.-P. Supervision: M.A.A.-P. Project administration: M.A.A.-P. Funding acquisition: M.A.A.-P., J.M. B., R.T., and S.F. The author(s) read and approved the final manuscript.

## Funding

This work was supported by the NC State University Chancellor's Innovation Fund (1108) (2018-2092). The UNC Microbiome Core is supported in part by the NIH grant P30 DK034987. R.T. is supported by NIH AI107029. S.F. received a postdoctoral fellowship from the Mexican Council on Science and Technology (CONACyT), grant number 205127.

## Availability of data and materials

All sequencing data has been submitted to the NCBI repository and can be accessed via the following accession numbers: mouse microbiota 16S rRNA amplicon sequencing PRJNA605460, whole-genome shotgun sequencing PRJNA605640, mouse mRNA sequencing PRJNA605019, and organoid 16S rRNA amplicon sequencing PRJNA606062.

## Ethics approval and consent to participate

All live animal studies were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of North Carolina at Chapel Hill (approved protocol numbers: 10-197, 16-080.0).

## Consent for publication

Not applicable.

## Competing interests

The authors declare that they have no competing interests.

## Author details

<sup>1</sup>Department of Medicine, Division of Gastroenterology and Hepatology, School of Medicine, University of North Carolina, Chapel Hill, NC, USA. <sup>2</sup>UNC Microbiome Core, Center for Gastrointestinal Biology and Disease (CGIBD), School of Medicine, University of North Carolina, Chapel Hill, NC, USA. <sup>3</sup>UNC Information Technology Services and Research Computing, University of North Carolina, Chapel Hill, NC, USA. <sup>4</sup>Current affiliation: Programa de Inmunología Molecular Microbiana. Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico. <sup>5</sup>Department of Cell Biology and Physiology, University of North Carolina, Chapel Hill, NC, USA. <sup>6</sup>Department of Plant and Microbial Biology, North Carolina State University, Raleigh, NC, USA. <sup>7</sup>Joint Department of Biomedical Engineering, University of North Carolina, Chapel Hill and North Carolina State University, Raleigh, NC, USA. <sup>8</sup>Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA.

Received: 21 August 2020 Accepted: 16 December 2020

Published online: 28 January 2021

## References

- Mitsuoka T. Intestinal flora and aging. *Nutr Rev.* 1992;50(12):438–46.
- Biagi E, et al. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. *PLoS One.* 2010;5(5):e10667.
- Mueller S, et al. Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study. *Appl Environ Microbiol.* 2006;72(2):1027–33.
- Hayashi H, et al. Molecular analysis of fecal microbiota in elderly individuals using 16S rDNA library and T-RFLP. *Microbiol Immunol.* 2003;47(8):557–70.
- Mariat D, et al. The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. *BMC Microbiol.* 2009;9:123.
- Rajilic-Stojanovic M, et al. Development and application of the human intestinal tract chip, a phylogenetic microarray: analysis of universally conserved phylotypes in the abundant microbiota of young and elderly adults. *Environ Microbiol.* 2009;11(7):1736–51.
- Woodmansey EJ, et al. Comparison of compositions and metabolic activities of fecal microbiotas in young adults and in antibiotic-treated and non-antibiotic-treated elderly subjects. *Appl Environ Microbiol.* 2004;70(10):6113–22.
- Bartosch S, et al. Characterization of bacterial communities in feces from healthy elderly volunteers and hospitalized elderly patients by using real-time PCR and effects of antibiotic treatment on the fecal microbiota. *Appl Environ Microbiol.* 2004;70(6):3575–81.
- van Tongeren SP, et al. Fecal microbiota composition and frailty. *Appl Environ Microbiol.* 2005;71(10):6438–42.
- Tiihonen K, et al. The effect of ageing with and without non-steroidal anti-inflammatory drugs on gastrointestinal microbiology and immunology. *Br J Nutr.* 2008;100(1):130–7.
- Makivuokko H, et al. The effect of age and non-steroidal anti-inflammatory drugs on human intestinal microbiota composition. *Br J Nutr.* 2010;103(2):227–34.
- Tiihonen K, Ouwehand AC, Rautonen N. Human intestinal microbiota and healthy ageing. *Ageing Res Rev.* 2010;9(2):107–16.
- Shin JH, High KP, Warren CA. Older is not wiser, immunologically speaking: effect of aging on host response to *Clostridium difficile* infections. *J Gerontol A Biol Sci Med Sci.* 2016;71(7):916–22.
- Drekonja D, et al. Fecal microbiota transplantation for *Clostridium difficile* infection: a systematic review. *Ann Intern Med.* 2015;162(9):630–8.
- Konturek PC, et al. Emerging role of fecal microbiota therapy in the treatment of gastrointestinal and extra-gastrointestinal diseases. *J Physiol Pharmacol.* 2015;66(4):483–91.
- Rampelli S, et al. Functional metagenomic profiling of intestinal microbiome in extreme ageing. *Ageing (Albany NY).* 2013;5(12):902–12.



17. Langille MG, et al. Microbial shifts in the aging mouse gut. *Microbiome*. 2014;2(1):50.
18. Elderman M, et al. The effect of age on the intestinal mucus thickness, microbiota composition and immunity in relation to sex in mice. *PLoS One*. 2017;12(9):e0184274.
19. Sovran B, et al. Age-associated impairment of the mucus barrier function is associated with profound changes in microbiota and immunity. *Sci Rep*. 2019;9(1):1437.
20. Kobayashi A, et al. The functional maturation of M cells is dramatically reduced in the Peyer's patches of aged mice. *Mucosal Immunol*. 2013;6(5):1027–37.
21. Arike L, Holmen-Larsson J, Hansson GC. Intestinal Muc2 mucin O-glycosylation is affected by microbiota and regulated by differential expression of glycosyltransferases. *Glycobiology*. 2017;27(4):318–28.
22. Arike L, Hansson GC. The densely O-glycosylated MUC2 mucin protects the intestine and provides food for the commensal bacteria. *J Mol Biol*. 2016;428(16):3221–9.
23. Johansson ME, et al. Normalization of host intestinal mucus layers requires long-term microbial colonization. *Cell Host Microbe*. 2015;18(5):582–92.
24. van Beek AA, et al. Supplementation with *Lactobacillus plantarum* WCFS1 prevents decline of mucus barrier in colon of accelerated aging Ercc1(-/ $\Delta$ 7) mice. *Front Immunol*. 2016;7:408.
25. van der Lugt B, et al. *Akkermansia muciniphila* ameliorates the age-related decline in colonic mucus thickness and attenuates immune activation in accelerated aging Ercc1 (-/ $\Delta$ 7) mice. *Immun Ageing*. 2019;16:6.
26. Karav S, Casaburi G, Frese SA. Reduced colonic mucin degradation in breastfed infants colonized by *Bifidobacterium longum* subsp. infantis EVC001. *FEBS Open Bio*. 2018;8(10):1649–57.
27. Schroeder BO, et al. *Bifidobacteria* or fiber protects against diet-induced microbiota-mediated colonic mucus deterioration. *Cell Host Microbe*. 2018;23(1):27–40 e7.
28. Thevaranjan N, et al. Age-associated microbial dysbiosis promotes intestinal permeability, systemic inflammation, and macrophage dysfunction. *Cell Host Microbe*. 2017;21(4):455–66 e4.
29. Maijo M, et al. Nutrition, diet and immunosenescence. *Mech Ageing Dev*. 2014;136–137:116–28.
30. Vasto S, et al. Inflammatory networks in ageing, age-related diseases and longevity. *Mech Ageing Dev*. 2007;128(1):83–91.
31. Sarkar D, Fisher PB. Molecular mechanisms of aging-associated inflammation. *Cancer Lett*. 2006;236(1):13–23.
32. Butto LF, Haller D. Dysbiosis in intestinal inflammation: cause or consequence. *Int J Med Microbiol*. 2016;306(5):302–9.
33. Carding S, et al. Dysbiosis of the gut microbiota in disease. *Microb Ecol Health Dis*. 2015;26:26191.
34. Buford TW. (Dis)Trust your gut: the gut microbiome in age-related inflammation, health, and disease. *Microbiome*. 2017;5(1):80.
35. Azcarate-Peril MA, et al. Analysis of the genome sequence of *Lactobacillus gasseri* ATCC 33323 reveals the molecular basis of an autochthonous intestinal organism. *Applied and Environmental Microbiology*. 2008;74(15):4610–25.
36. Vandenplas Y, Zakharova I, Dmitrieva Y. Oligosaccharides in infant formula: more evidence to validate the role of prebiotics. *Br J Nutr*. 2015;113(9):1339–44.
37. Akkerman R, Faas MM, de Vos P. Non-digestible carbohydrates in infant formula as substitution for human milk oligosaccharide functions: Effects on microbiota and gut maturation. *Crit Rev Food Sci Nutr*. 2019;59(9):1486–97.
38. Bhatia S, et al. Galacto-oligosaccharides may directly enhance intestinal barrier function through the modulation of goblet cells. *Mol Nutr Food Res*. 2015;59(3):566–73.
39. Akbari P, et al. Galacto-oligosaccharides protect the intestinal barrier by maintaining the tight junction network and modulating the inflammatory responses after a challenge with the mycotoxin deoxynivalenol in human Caco-2 cell monolayers and B6C3F1 mice. *J Nutr*. 2015;145(7):1604–13.
40. Alizadeh A, et al. The piglet as a model for studying dietary components in infant diets: effects of galacto-oligosaccharides on intestinal functions. *Br J Nutr*. 2016;115(4):605–18.
41. Davis LM, et al. Barcoded pyrosequencing reveals that consumption of galactooligosaccharides results in a highly specific bifidogenic response in humans. *PLoS One*. 2011;6(9):e25200.
42. Scalabrin DM, et al. New prebiotic blend of polydextrose and galacto-oligosaccharides has a bifidogenic effect in young infants. *J Pediatr Gastroenterol Nutr*. 2012;54(3):343–52.
43. Salvini F, et al. A specific prebiotic mixture added to starting infant formula has long-lasting bifidogenic effects. *J Nutr*. 2011;141(7):1335–9.
44. Rowland IR, Tanaka R. The effects of transgalactosylated oligosaccharides on gut flora metabolism in rats associated with a human faecal microflora. *J Appl Bacteriol*. 1993;74(6):667–74.
45. Monteagudo-Mera A, et al. High purity galacto-oligosaccharides enhance specific *Bifidobacterium* species and their metabolic activity in the mouse gut microbiome. *Benef Microbes*. 2016;3:1–18.
46. Azcarate-Peril MA, et al. Microbiome alterations of lactose intolerant individuals in response to dietary intervention with galacto-oligosaccharides may help negate symptoms of lactose intolerance. *Gastroenterology*. 2013;144(5):S–893.
47. Azcarate-Peril MA, et al. Impact of short-chain galactooligosaccharides on the gut microbiome of lactose-intolerant individuals. *Proc Natl Acad Sci U S A*. 2017;114(3):E367–75.
48. Vulevic J, et al. Modulation of the fecal microflora profile and immune function by a novel trans-galactooligosaccharide mixture (B-GOS) in healthy elderly volunteers. *Am J Clin Nutr*. 2008;88(5):1438–46.
49. Dagher SF, Azcarate-Peril MA, Bruno-Barcena JM. Heterologous expression of a bioactive beta-hexosyltransferase, an enzyme producer of prebiotics, from *Sporobolomyces singularis*. *Appl Environ Microbiol*. 2013;79(4):1241–9.
50. Giarratano A, Green SE, Nicolau DP. Review of antimicrobial use and considerations in the elderly population. *Clin Interv Aging*. 2018;13:657–67.
51. Van Boeckel TP, et al. Global trends in antimicrobial use in food animals. *Proc Natl Acad Sci U S A*. 2015;112(18):5649–54.
52. Dethlefsen, L. and D.A. Relman. Microbes and Health Sackler Colloquium: incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. *Proc Natl Acad Sci U S A*.
53. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. *Proc Natl Acad Sci U S A*. 2011;108(Suppl 1):4554–61.
54. Williamson IA, et al. A high-throughput organoid microinjection platform to study gastrointestinal microbiota and luminal physiology. *Cell Mol Gastroenterol Hepatol*. 2018;6(3):301–19.
55. Vulevic J, et al. Influence of galacto-oligosaccharide mixture (B-GOS) on gut microbiota, immune parameters and metabolomics in elderly persons. *Br J Nutr*. 2015;114(4):586–95.
56. Arnold JW, et al. Prebiotics for lactose intolerance: variability in galacto-oligosaccharide utilization by intestinal *Lactobacillus rhamnosus*. *Nutrients*. 2018;10(10):1517. <https://doi.org/10.3390/nu10101517>.
57. Rios-Covian D, et al. Enhanced butyrate formation by cross-feeding between *Faecalibacterium prausnitzii* and *Bifidobacterium adolescentis*. *FEMS Microbiol Lett*. 2015;362(21):fnv176. <https://doi.org/10.1093/femsle/fnv176>. Epub 2015 Sep 28.
58. Riviere A, et al. *Bifidobacteria* and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut. *Front Microbiol*. 2016;7:979.
59. Sivaprakasam S, Prasad PD, Singh N. Benefits of short-chain fatty acids and their receptors in inflammation and carcinogenesis. *Pharmacol Ther*. 2016;164:144–51. <https://doi.org/10.1016/j.pharmthera.2016.04.007>. Epub 2016 Apr 23.
60. Lewis K, et al. Enhanced translocation of bacteria across metabolically stressed epithelia is reduced by butyrate. *Inflamm Bowel Dis*. 2010;16(7):1138–48.
61. Gaudier E, et al. Butyrate regulation of glycosylation-related gene expression: evidence for galectin-1 upregulation in human intestinal epithelial goblet cells. *Biochem Biophys Res Commun*. 2004;325(3):1044–51.
62. Renes IB, et al. Epithelial proliferation, cell death, and gene expression in experimental colitis: alterations in carbonic anhydrase I, mucin MUC2, and trefoil factor 3 expression. *Int J Colorectal Dis*. 2002;17(5):317–26.
63. Aihara E, Engevik KA, Montrose MH. Trefoil factor peptides and gastrointestinal function. *Annu Rev Physiol*. 2017;79:357–80.
64. Hogan SP, et al. Resistin-like molecule beta regulates innate colonic function: barrier integrity and inflammation susceptibility. *J Allergy Clin Immunol*. 2006;118(1):257–68.
65. Bouchlaka MN, et al. Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy. *J Exp Med*. 2013;210(11):2223–37.
66. Starr ME, et al. Age-associated increase in cytokine production during systemic inflammation-II: the role of IL-1 $\beta$  in age-dependent IL-6 upregulation in adipose tissue. *J Gerontol A Biol Sci Med Sci*. 2015;70(12):1508–15.

67. Szklarczyk D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res.* 2019;47(D1):D607–13.
68. Metsalu T, Vilo J. ClustVis: a web tool for visualizing clustering of multivariate data using principal component analysis and heatmap. *Nucleic Acids Res.* 2015;43(W1):W566–70.
69. Laaf D, et al. Galectin-carbohydrate interactions in biomedicine and biotechnology. *Trends Biotechnol.* 2019;37(4):402–15.
70. Li FY, et al. Galectins in host defense against microbial infections. *Adv Exp Med Biol.* 2020;1204:141–67.
71. Jones RM, Neish AS. Redox signaling mediated by the gut microbiota. *Free Radic Biol Med.* 2017;105:41–7.
72. Clapham DE, Runnels LW, Strubing C. The TRP ion channel family. *Nat Rev Neurosci.* 2001;2(6):387–96.
73. Williamson IT, et al. A high-throughput organoid microinjection platform to study gastrointestinal microbiota and luminal physiology. *Cell Mol Gastroenterol Hepatol.* 2018;6(3):301, 319.
74. Shoaf K, et al. Prebiotic galactooligosaccharides reduce adherence of enteropathogenic *Escherichia coli* to tissue culture cells. *Infection and Immunity.* 2006;74(12):6920–8.
75. Zhao S, et al. *Akkermansia muciniphila* improves metabolic profiles by reducing inflammation in chow diet-fed mice. *J Mol Endocrinol.* 2017; 58(1):1–14.
76. Collado MC, et al. Intestinal integrity and *Akkermansia muciniphila*, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly. *Appl Environ Microbiol.* 2007;73(23):7767–70.
77. Nicoletti C. Age-associated changes of the intestinal epithelial barrier: local and systemic implications. *Expert Rev Gastroenterol Hepatol.* 2015;9(12):1467–9.
78. Zwielehner J, et al. Combined PCR-DGGE fingerprinting and quantitative-PCR indicates shifts in fecal population sizes and diversity of Bacteroides, bifidobacteria and *Clostridium* cluster IV in institutionalized elderly. *Exp Gerontol.* 2009;44(6-7):440–6.
79. Raul F, et al. Age related increase of brush border enzyme activities along the small intestine. *Gut.* 1988;29(11):1557–63.
80. Lee MF, et al. Total intestinal lactase and sucrase activities are reduced in aged rats. *J Nutr.* 1997;127(7):1382–7.
81. Matsuki T, et al. Infant formula with galacto-oligosaccharides (OM55N) stimulates the growth of indigenous bifidobacteria in healthy term infants. *Benef Microbes.* 2016;7(4):453–61.
82. So D, et al. Dietary fiber intervention on gut microbiota composition in healthy adults: a systematic review and meta-analysis. *Am J Clin Nutr.* 2018; 107(6):965–83.
83. Szklany K, et al. Supplementation of dietary non-digestible oligosaccharides from birth onwards improve social and reduce anxiety-like behaviour in male BALB/c mice. *Nutr Neurosci.* 2019:1–15.
84. Cheng W, et al. Effect of functional oligosaccharides and ordinary dietary fiber on intestinal microbiota diversity. *Front Microbiol.* 2017;8:1750.
85. Chen X, et al. A mouse model of *Clostridium difficile*-associated disease. *Gastroenterology.* 2008;135(6):1984–92.
86. Reikvam DH, et al. Depletion of murine intestinal microbiota: effects on gut mucosa and epithelial gene expression. *PLoS One.* 2011;6(3):e17996.
87. Zimmermann P, Curtis N. The effect of antibiotics on the composition of the intestinal microbiota - a systematic review. *J Infect.* 2019;79(6):471–89.
88. Barbut F, Meynard JL. Managing antibiotic associated diarrhoea. *BMJ.* 2002; 324(7350):1345–6.
89. Ladirat SE, et al. Impact of galacto-oligosaccharides on the gut microbiota composition and metabolic activity upon antibiotic treatment during *in vitro* fermentation. *FEMS Microbiol Ecol.* 2014;87(1):41–51.
90. Kudryavtseva AV, et al. Mitochondrial dysfunction and oxidative stress in aging and cancer. *Oncotarget.* 2016;7(29):44879–905.
91. Vartak R, Porras CA, Bai Y. Respiratory supercomplexes: structure, function and assembly. *Protein Cell.* 2013;4(8):582–90.
92. Arslanoglu S, et al. Early dietary intervention with a mixture of prebiotic oligosaccharides reduces the incidence of allergic manifestations and infections during the first two years of life. *J Nutr.* 2008;138(6):1091–5.
93. Schouten B, et al. Oligosaccharide-induced whey-specific CD25(+) regulatory T-cells are involved in the suppression of cow milk allergy in mice. *J Nutr.* 2010;140(4):835–41.
94. van der Aa LB, et al. Effect of a new synbiotic mixture on atopic dermatitis in infants: a randomized-controlled trial. *Clin Exp Allergy.* 2010;40(5):795–804.
95. de Kivit S, et al. Glycan recognition at the interface of the intestinal immune system: target for immune modulation via dietary components. *Eur J Pharmacol.* 2011;668(Suppl 1):S124–32.
96. Garin MI, et al. Galectin-1: a key effector of regulation mediated by CD4+ CD25+ T cells. *Blood.* 2007;109(5):2058–65.
97. van der Leij J, et al. Strongly enhanced IL-10 production using stable galectin-1 homodimers. *Mol Immunol.* 2007;44(4):506–13.
98. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. *Nat Rev Mol Cell Biol.* 2005;6(1):56–68.
99. Petit V, Thiery JP. Focal adhesions: structure and dynamics. *Biol Cell.* 2000; 92(7):477–94.
100. Arnold JW, Roach J, Azcarate-Peril MA. Emerging technologies for gut microbiome research. *Trends Microbiol.* 2016;24(11):887–901.
101. Tran L, Greenwood-Van Meerveld B. Age-associated remodeling of the intestinal epithelial barrier. *J Gerontol A Biol Sci Med Sci.* 2013;68(9):1045–56.
102. Mitchell EL, et al. Reduced intestinal motility, mucosal barrier function, and inflammation in aged monkeys. *J Nutr Health Aging.* 2017;21(4):354–61.
103. Zhang Y, et al. Effect of heat-inactivated *Lactobacillus paracasei* N1115 on microbiota and gut-brain axis related molecules. *Biosci Microbiota Food Health.* 2020;39(3):89–99.
104. Gracz AD, et al. A high-throughput platform for stem cell niche co-cultures and downstream gene expression analysis. *Nat Cell Biol.* 2015;17(3):340–9.
105. Wang Y, et al. *In vitro* generation of colonic epithelium from primary cells guided by microstructures. *Lab Chip.* 2014;14(9):1622–31.
106. Junick J, Blaut M. Quantification of human fecal bifidobacterium species by use of quantitative real-time PCR analysis targeting the *groEL* gene. *Appl Environ Microbiol.* 2012;78(8):2613–22.
107. Matsuki T, et al. Quantitative PCR with 16S rRNA-gene-targeted species-specific primers for analysis of human intestinal bifidobacteria. *Appl Environ Microbiol.* 2004;70(1):167–73.
108. Hermann-Bank, M.L., et al. The gut microbiotassay: a high-throughput qPCR approach combinable with next generation sequencing to study gut microbial diversity. *BMC Genomics.* 2013;14:788.
109. Kwon H-S, et al. Rapid identification of potentially probiotic *Bifidobacterium* species by multiplex PCR using species-specific primers based on the region extending from 16S rRNA through 23S rRNA. *FEMS Microbiol Lett.* 2006; 250(1):55–62.
110. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. *Nat Protoc.* 2008;3(6):1101–8.
111. Bolyen E, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. *Nat Biotechnol.* 2019;37(8):852–7.
112. Vieira-Silva S, et al. Species-function relationships shape ecological properties of the human gut microbiome. *Nat Microbiol.* 2016;1(8):16088.
113. Magnusdottir S, et al. Generation of genome-scale metabolic reconstructions for 773 members of the human gut microbiota. *Nat Biotechnol.* 2017;35(1):81–9.
114. Paul De Vos, e., *Bergey's manual of systematic bacteriology: 2nd Dordrecht; Springer, [2009] ©2009.*
115. Maruo T, et al. *Adlercreutzia equolifaciens* gen. nov., sp. nov., an equol-producing bacterium isolated from human faeces, and emended description of the genus *Eggerthella*. *Int J Syst Evol Microbiol.* 2008;58(Pt 5): 1221–7.
116. Monteiro RA, et al. Use of lactose to induce expression of soluble NifA protein domains of *Herbaspirillum seropedicae* in *Escherichia coli*. *Can J Microbiol.* 2000;46(11):1087–90.
117. Brooke JS. *Stenotrophomonas maltophilia*: an emerging global opportunistic pathogen. *Clin Microbiol Rev.* 2012;25(1):2–41.
118. Kooken JM, Fox KF, Fox A. Characterization of *Micrococcus* strains isolated from indoor air. *Mol Cell Probes.* 2012;26(1):1–5.
119. Kuete E, et al. *Brachybacterium timonense* sp. nov., a new bacterium isolated from human sputum. *New Microbes New Infect.* 2019;31:100568.
120. Duskova D, Marounek M. Fermentation of pectin and glucose, and activity of pectin-degrading enzymes in the rumen bacterium *Lachnospira multiparus*. *Lett Appl Microbiol.* 2001;33(2):159–63.
121. Kasperowicz A, et al. Sucrose phosphorylase of the rumen bacterium *Pseudobutyrvibrio ruminis* strain A. *J Appl Microbiol.* 2009;107(3):812–20.
122. Petzel JP, Hartman PA. Aromatic amino acid biosynthesis and carbohydrate catabolism in strictly anaerobic mollicutes (*Anaeroplasma* spp.). *Systematic and Applied Microbiology.* 1990;13(3):240–7.
123. Wallace RJ, et al. *Eubacterium pyruvivorans* sp. nov., a novel non-saccharolytic anaerobe from the rumen that ferments pyruvate and amino

- acids, forms caproate and utilizes acetate and propionate. *Int J Syst Evol Microbiol.* 2003;53(Pt 4):965–70.
124. Tarlera S, et al. *Caloramator proteoclasticus* sp. nov., a new moderately thermophilic anaerobic proteolytic bacterium. *Int J Syst Bacteriol.* 1997; 47(3):651–6.
  125. Collins MD, et al. Phenotypic and phylogenetic characterization of some Globicatella-like organisms from human sources: description of *Facklamia hominis* gen. nov., sp. nov. *Int J Syst Bacteriol.* 1997;47(3):880–2.
  126. Heyndrickx M, et al. Proposal of *Virgibacillus proomii* sp. nov. and emended description of *Virgibacillus pantothenicus* (Proom and Knight 1950) Heyndrickx et al. 1998. *Int J Syst Bacteriol.* 1999;49(Pt 3):1083–90.
  127. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nat Methods.* 2012;9(4):357–9.
  128. Abubucker S, et al. Metabolic reconstruction for metagenomic data and its application to the human microbiome. *PLoS Comput Biol.* 2012;8(6): e1002358.
  129. Okazaki R, et al. The crucial role of Erk2 in demyelinating inflammation in the central nervous system. *J Neuroinflamm.* 2016;13(1):235.
  130. Yang Y, et al. Chemoprevention of dietary digitoflavone on colitis-associated colon tumorigenesis through inducing Nrf2 signaling pathway and inhibition of inflammation. *Mol Cancer.* 2014;13(1):48.
  131. Shigemura H. Up-regulation of MUC2 mucin expression by serum amyloid A3 protein in mouse. *J Vet Med Sci.* 2014;76(7):985–91. <https://doi.org/10.1292/jvms.14-0007>. Epub 2014 Apr 1.
  132. Wlodarska M, et al. Antibiotic treatment alters the colonic mucus layer and predisposes the host to exacerbated *Citrobacter rodentium*-induced colitis. *Infect Immun.* 2011;79(4):1536–45.
  133. Morampudi V, et al. The goblet cell-derived mediator RELM-beta drives spontaneous colitis in Muc2-deficient mice by promoting commensal microbial dysbiosis. *Mucosal Immunol.* 2016;9(5):1218–33.
  134. Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics.* 2013;29(1):15–21.
  135. Patro R, et al. Salmon provides fast and bias-aware quantification of transcript expression. *Nat Methods.* 2017;14(4):417–9.
  136. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* 2014;15(12):550.
  137. Mandal S, et al. Analysis of composition of microbiomes: a novel method for studying microbial composition. *Microb Ecol Health Dis.* 2015;26:27663.
  138. Parks DH, et al. STAMP: statistical analysis of taxonomic and functional profiles. *Bioinformatics.* 2014;30(21):3123–4.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

